Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-01-31
2006-01-31
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S135100, C424S141100, C424S158100
Reexamination Certificate
active
06991791
ABSTRACT:
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
REFERENCES:
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4822776 (1989-04-01), Cerami et al.
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5342613 (1994-08-01), Creaven et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5993833 (1999-11-01), DeLacharriere et al.
patent: 6190691 (2001-02-01), Mak
patent: 6309640 (2001-10-01), Cerami et al.
patent: 6419927 (2002-07-01), Cerami et al.
patent: 42 02 665 (1992-01-01), None
patent: 0212489 (1987-03-01), None
patent: 0218868 (1987-04-01), None
patent: 0260610 (1988-03-01), None
patent: 0288088 (1988-10-01), None
patent: 0308378 (1989-03-01), None
patent: 0350690 (1990-01-01), None
patent: 0351789 (1990-01-01), None
patent: 0380068 (1990-08-01), None
patent: 0393438 (1990-10-01), None
patent: 0398327 (1990-11-01), None
patent: 0412486 (1991-02-01), None
patent: 0486526 (1991-03-01), None
patent: 0433900 (1991-06-01), None
patent: 0526905 (1993-02-01), None
patent: 0101681 (1994-12-01), None
patent: 90/00902 (1990-02-01), None
patent: WO91/02078 (1991-02-01), None
patent: 91/09967 (1991-07-01), None
patent: WO91/09967 (1991-07-01), None
patent: WO 92/16553 (1992-03-01), None
patent: WO92/07076 (1992-04-01), None
patent: WO92/02190 (1992-06-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO92/13095 (1992-08-01), None
patent: WO 93/02108 (1993-02-01), None
Partridge, Trends in Biotechnology, 1994, vol. 12, pp. 239-245. Abstract.
Beck et al (Acta Neurologica Scandinavica, Oct. 1988, vol. 78, pp. 318-323).
abstract of Beck et al (Immunobiology, 1987, vol. 175, pp. 91-92).
abstract of Selmaj et al (Neuroimmunology, 1987, vol. 16, p. 159).
Beutler, B. et al., “Identity of tumour necrosis factor and the macrophage-secreted factor cachectin,”Nature, 316:552-554 (1985).
Beutler, B. et al., “Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin,”Science, 229:869-871 (1985).
Morrison, Sherie L., “Transfectomas Provide Novel Chimeric Antibodies,”Science, 229:1202-1207 (1985).
Liang, Chi-Ming et al., “Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin,”Biochem.&Biophys. Res. Comm., 137(2):847-854 (1986).
Hirai, Makoto et al., “Production and characterization of monoclonal antibodies to human tumor necrosis factor,”J. of Immun. Methods, 96:57-62 (1987).
Piguet, Pierre-Francois et al., “Tumor Necrosis Factor/Cacectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease,”J. Exp. Med., 166:1280-1289 (1987).
Meager, Anthony et al., “Preparation and Charaterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF),”Hybridoma, 6(3):305-311 (1987).
Fendly, Brian M. et al., “Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor,”Hybridoma, 6(4):359-370 (1987).
Bringman, Timothy S. and Aggarwal, Bharat B., “Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes,”Hybridoma, 6(5):489-507 (1987).
Tracey, Kevin J. et al., “Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia,”Nature, 330:662-664 (1987).
Nagai, M. et al., “Antibody to tumor necrosis factor (TNF) reduces endotoxin fever,”Experientia, 44:606-607 (1988).
Shimamoto, Yoshinori et al., “Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock,”Immunology Letters, 17:311-318 (1988).
Di Giovine, Francesco, S. et al., “Tumour necrosis factor in synovial exudates,”Annals of the Rheumatic Diseases, 47:768-771 (1988).
Collins, M.S. et al., “Immunoprophylaxis of Polymicrobic Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen ofPseudomonas aeruginosa,” Abstract E-63,Absstracts of Annual Meeting 1989.
Exley, A.R. et al., “Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys,”Medical Research Society,Abstract 184, p. 50 (1989).
Cross, A.S. et al., “Pretreatment with Recombinant Murine Tumor Necrosis Factor α/Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection,”J of Exp Med., 169:2021-2027 (1989).
Engelmann, Hartmut et al., “A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity,”J. of Bio. Chem., 264(20):11974-11980 (1989).
Kawasaki, Hajime et al., “Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin),”Infection and Immunity, 57(10):3131-3135 (1989).
Fong, Yuman et al., “Antibodies to Cachetin/Tumor Necrosis Factor Reduce Interleukin 1β and Interleukin 6 Appearance During Lethal Bacteremia,”J. Exp. Med., 170:1627-1633 (1989).
Von Asmuth, E.J.U. et al., “Tumour Necrosis Factor Alpha (TNA-α) and Interleukin 6 in a Zymosan-Induced Shock Model,”Scand. J. Immunol., 32:313-319 (1990).
Herve, P. et al., “Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans,” Abstract 3.25,Lymphoma Res. 9:591 (1990).
Silva, Ayona T. et al., “Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor-α in Experimental Gram-Negative Shock,”J. of Infectious Diseases, 162:421-427 (1990).
Opal, Steven M. et al., “Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection withPseudomonas aeruginosa,” J. of Infectious Diseases 161:1148-1152 (1990).
Tavernier, Jan et al., “Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis,”J. Mol. Biol., 211:493-501 (1990).
Lucas, R. et al., “Generation and characterization of a neutralizing rat anti-rm TNF-α monoclonal antibody,”Immunology, 71:218-223 (1990).
Hinshaw, L.B. et al., “Survival of Primates in LD100Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNFα),”Circulatory Shock, 30:279-292 (1990).
Nophar, Yaron et al., “Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor,”The EMBO Journal, 9(10):3269-3278 (1990).
Engelmann, Hartmut et al., “Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine,”J. of Bio. Chem., 265(3):1531-1536 (1990).
Verhoef, J. and Torensma, R., “Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections,”Eur. J. Clin. Microbiol. Dis., 9(4):247-250 (1990).
Loetscher, Hansruedi et al., “Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor,”Cell, 61:351-359 (1990).
Schall, Thomas J. et al., “Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor,”Cell, 61:361-370 (1990).
A
Daddona Peter
Ghrayeb John
Knight David
Le Junming
Siegel Scott
Canella Karen A.
Centocor, Inc.
Hamilton Brook Smith & Reynolds P.C.
New York University School of Medicine
LandOfFree
Anti-TNF antibodies and peptides of human tumor necrosis factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-TNF antibodies and peptides of human tumor necrosis factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-TNF antibodies and peptides of human tumor necrosis factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3529477